Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| Weiss Ratings | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.49% | |||
| 30-Day Total Return | -33.33% | |||
| 60-Day Total Return | -87.60% | |||
| 90-Day Total Return | -88.82% | |||
| Year to Date Total Return | -35.03% | |||
| 1-Year Total Return | -91.54% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -91.85% | |||
| 52-Week Low % Change | 11.11% | |||
| Price | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $17.19 | |||
| 52-Week Low Price | $1.26 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Oct 18, 2024 | |||
| Valuation | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 226.77M | |||
| Enterprise Value | -78.95M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.53 | |||
| Earnings Per Share Growth | -64.79% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.79 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.28 | |||
| Enterprise Value/EBITDA (TTM) | 0.30 | |||
| Enterprise Value/EBIT | 0.30 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 160.98M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 760 0900 | |||
| Address | 490 Arsenal Way Watertown, MA 02472 | |||
| Website | www.neumoratx.com | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -40.50% | |||
| Return on Equity | -- | |||
| Income Statement | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -262.83M | |||
| EBIT (TTM) | -263.46M | |||
| Net Income (TTM) | -243.79M | |||
| Net Income Avl. to Common (TTM) | -243.79M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 45.90% | |||
| EPS Diluted (TTM) | -1.53 | |||
| EPS Diluted Growth (Q YOY) | 48.64% | |||
| Balance Sheet | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 307.58M | |||
| Cash Per Share (Q) | $1.91 | |||
| Total Current Assets (Q) | 314.06M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 287.06M | |||
| Current Ratio (Q) | 10.508 | |||
| Book Value Per Share (Q) | $1.78 | |||
| Total Assets (Q) | 316.97M | |||
| Total Current Liabilities (Q) | 29.89M | |||
| Total Debt (Q) | 1.85M | |||
| Total Liabilities (Q) | 29.91M | |||
| Total Common Equity (Q) | 287.06M | |||
| Cash Flow | NMRA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -70.56M | |||
| Cash from Financing (TTM) | 21.60M | |||
| Net Change in Cash (TTM) | -231.89M | |||
| Levered Free Cash Flow (TTM) | -100.70M | |||
| Cash from Operations (TTM) | -182.94M | |||
